Literature DB >> 28331458

Immune Thrombocytopenia and Obesity: Predictive Relationship.

Ehab Hanafy1, Mohammed Al Pakra1.   

Abstract

BACKGROUND: Chronic refractory immune thrombocytopenia (ITP) is defined as the failure of any modality to maintain the platelet count above 20 × 103/μL for an appreciable time without unacceptable toxicity. To date, certain predictive factors have been associated with refractory ITP. However, none of the published studies has declared the possible association between obesity and refractory ITP. CASE REPORTS: We present the cases of 3 children with ITP who failed to achieve remission on different therapeutic approaches including rituximab, vincristine, and romiplostim. The 3 children had obesity as a common feature.
CONCLUSION: We present these cases to propose a possible association between obesity and refractoriness of ITP to different therapeutic approaches and to emphasize the need for further study to establish whether a causal relationship exists.

Entities:  

Keywords:  Pediatric obesity; purpura–thrombocytopenic–idiopathic

Year:  2017        PMID: 28331458      PMCID: PMC5349622     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  9 in total

Review 1.  Management of patients with refractory immune thrombocytopenic purpura.

Authors:  J N George
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

2.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

Review 3.  Refractory immune thrombocytopenic purpura: current strategies for investigation and management.

Authors:  Bethan Psaila; James B Bussel
Journal:  Br J Haematol       Date:  2008-10       Impact factor: 6.998

4.  Management of immune thrombocytopenic purpura: an update.

Authors:  Rajasekharan Warrier; Aman Chauhan
Journal:  Ochsner J       Date:  2012

Review 5.  Congenital and acquired thrombocytopenia.

Authors:  Douglas B Cines; James B Bussel; Robert B McMillan; James L Zehnder
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

6.  Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.

Authors:  S Z Latifzadeh; V Entezari
Journal:  Clin Appl Thromb Hemost       Date:  2006-10       Impact factor: 2.389

7.  Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease.

Authors:  Bernward Zeller; Jukka Rajantie; Iris Hedlund-Treutiger; Ulf Tedgård; Finn Wesenberg; Olafur G Jonsson; Jan Inge Henter
Journal:  Acta Paediatr       Date:  2005-02       Impact factor: 2.299

8.  [Thrombocytopenic idiopathic purpura: predictive factors for chronic disease].

Authors:  Sonia Mazigh Mrad; Monia Ouedemi; Olfa Bouyahia; Lamia Gharsallah; Samir Boukthir; Azza Samoud Gharbi
Journal:  Tunis Med       Date:  2009-01

9.  Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report.

Authors:  Sarah E Barlow
Journal:  Pediatrics       Date:  2007-12       Impact factor: 7.124

  9 in total
  1 in total

1.  Association between Helicobacter pylori infection and platelet count in mice.

Authors:  Teruko Fukuda; Eri Asou; Kimiko Nogi; Masahiko Yasuda; Kazuo Goto
Journal:  Exp Anim       Date:  2018-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.